SOURCE: NeuroInvestment


October 06, 2010 10:20 ET

Therapeutics for Anxiety Reviewed by NeuroInvestment

CARDIFF, CA--(Marketwire - October 6, 2010) -  NI Research has released the October issue of NeuroInvestment, which features a comprehensive review of therapeutics for the treatment of anxiety.

Anxiety has become ubiquitous in the First World, and with so many triggers reflecting forces and factors out of our control -- ranging from economic malaise to terrorism to post-combat traumatic stress -- this will not change anytime soon. In spite of the fortune spent by pharmaceutical firms over the past fifty years, no ideal anxiolytic has been yet discovered. In fact, since we published our first review of the anxiety field in 1995, the number of groundbreaking new anxiety medications is... zero. That is not to say that nothing has been approved in that time, several SSRIs and anticonvulsants have added anxiolysis to their roster of putative targets. These drugs have some utility, although for many patients, their side effects mean that the 'cure' can seem almost as bad as the disease itself. But anxiety is an afterthought for these newer drugs, all of which have primary indications elsewhere, and for whom anxiety primarily represents an attempt to broaden the market. None of them has provided a substantive new avenue to anxiolysis. Novel approaches, such as CRF antagonism, have thus far produced little beyond clinical trial disappointment. Results from a recent trial conducted by the company BrainCells also raise fundamental questions as to how the constructs of depression and anxiety interface, and should optimally be addressed.

Over 30 therapeutics programs are included in this anxiolysis review. They include CRF programs from GSK/Neurocrine Biosciences, Bristol-Myers Squibb, CeNeRx, Ono, Sanofi-Aventis, and Taisho; mGluR approaches from Addex, AstraZeneca, Novartis, Lilly; and an array of other tactics including 5HT6/7, oxytocin, and cannabinoids.

The October issue also considers:

1) the advent of the oral immunotherapy era in Multiple Sclerosis (Novartis and possibly, Merck Serono)

2) the most recent corporate headlines from Elan, concluding that when it comes to Elan management, 2010 is (or should be) the new 2012

3) A succinct assessment of the nascent mood disorder company Euthymics Bioscience

NeuroInvestment is the independent, monthly review of the neurotherapeutics area. Its reputation has been built upon fifteen years of objective, insightful, and critical coverage of the neurotherapeutics field. A one-year, five-user subscription is $2100, email or hardcopy. Add $250 for dual delivery, add $50 for airmail delivery outside North America. A three month email trial is US$700. The October issue is available as a single purchase, for US$300.

The September issue of NeuroInvestment reviewed Alzheimer's therapeutics, and the forthcoming November issue will review programs for the treatment of neuropathic pain.

NI Research is the leading publisher of independent research on the neurotherapeutics industry. NI Research has published NeuroInvestment since 1995, the Private CNS Company Review since 2003, and CNS Disorders/Therapeutics since 2007. NI Research also provides strategic consultation services. NI Research has developed an unmatched information base regarding both publicly and privately-held neuro-oriented companies.

Contact Information